Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2002 Feb;13(2):293-8.

Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women.

Author information

  • 1Department of Medical Oncology, Institut BergoniĆ©, Regional Cancer Center, Bordeaux, France. mauriac@bergonie.org

Abstract

BACKGROUND:

From 1984 to 1996, 1581 postmenopausal women aged 50-70 years old were treated at Institut BergoniƩ for an infiltrative non-metastatic breast carcinoma with a positive estrogen and/or progesterone receptor determination.

PATIENTS AND METHODS:

Among them, 199 were treated with first line tamoxifen. Ninety-seven had operable disease (T2 >30 mm, T3, N0/1) and 102 had T4 tumours.

RESULTS:

After a mean treatment duration of 5.3 months, 89 T2 and T3 (92%) and 93 T4 (91%) were treated by surgery (conservative or not) with or without irradiation, or by irradiation alone. Conserving treatment levels were 53.6% and 44%, respectively. The other women were treated with either second-line chemotherapy or another hormonotherapy; the remaining patients continued regularly with tamoxifen. Overall survival is analysed with a 83 month median follow-up.

CONCLUSIONS:

A comparison between neoadjuvant endocrine therapy and surgery seems feasible to assess the concept of neoadjuvant hormonotherapy.

PMID:
11886008
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk